EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)

Brentuximab vedotin with dacarbazine or nivolumab as frontline cHL therapy for older patients ineligible for chemotherapy

Jonathan W Friedberg iD, Rodolfo Bordoni, Dipti Patel-Donnelly, Timothy Larson, Jerome Goldschmidt, Ralph Boccia, Vivian J M Cline, Adrija Mamidipalli, Jingmin Liu, Alev Akyol, Christopher A Yasenchak iD

Blood · 2024

DOI: 10.1182/blood.2022019536 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Blood, 2024. Verfasst von Jonathan W Friedberg und 10 weiteren Autor:innen. Beteiligte Einrichtung: Wilmot Cancer Institute, University of Rochester, Rochester, NY. Hauptthemen laut MEDLINE: Frailty, Hodgkin Disease, Immunoconjugates. Die Arbeit wurde bisher 46-mal zitiert (Crossref) und nennt 32 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Older patients with advanced-stage classical Hodgkin lymphoma (cHL) have inferior outcomes compared with younger patients, potentially due to comorbidities and frailty. This noncomparative phase 2 study enrolled patients aged ≥60 years with cHL unfit for conventional chemotherapy to receive frontline brentuximab vedotin (BV; 1.8 mg/kg) with dacarbazine (DTIC; 375 mg/m2) (part B) or nivolumab (part D; 3 mg/kg). In parts B and D, 50% and 38% of patients, respectively, had ≥3 general comorbidities or ≥1 significant comorbidity. Of the 22 patients treated with BV-DTIC, 95% achieved objective response, and 64% achieved complete response (CR). With a median follow-up of 63.6 months, median duration of response (mDOR) was 46.0 months. Median progression-free survival (mPFS) was 47.2 months; median overall survival (mOS) was not reached. Of 21 patients treated with BV-nivolumab, 86% achieved objective response, and 67% achieved CR. With 51.6 months of median follow-up, mDOR, mPFS, and mOS were not reached. Ten patients (45%) with BV-DTIC and 16 patients (76%) with BV-nivolumab experienced grade ≥3 treatment-emergent adverse events; sensory peripheral neuropathy (PN; 27%) and neutropenia (9%) were most common with BV-DTIC, and increased lipase (24%), motor PN (19%), and sensory PN (19%) were most common with BV-nivolumab. Despite high median age, inclusion of patients aged ≤88 years, and frailty, these results demonstrate safety and promising durable efficacy of BV-DTIC and BV-nivolumab combinations as frontline treatment, suggesting potential alternatives for older patients with cHL unfit for initial conventional chemotherapy. This trial was registered at www.clinicaltrials.gov as #NCT01716806.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

FrailtyHodgkin DiseaseImmunoconjugatesAged, 80 and overHumansAntineoplastic Combined Chemotherapy ProtocolsBrentuximab VedotinDacarbazineNivolumab

Substanzen

Brentuximab VedotinDacarbazineImmunoconjugatesNivolumab

Autor:innen und Institutionen

  • Wilmot Cancer Institute, University of Rochester, Rochester, NY.
  • Georgia Cancer Specialists, Marietta, GA.
  • Virginia Cancer Specialists, Fairfax, VA.
  • Minnesota Oncology PA, Minneapolis, MN.
  • Oncology and Hematology Associates of SW Virginia, Blacksburg, VA.
  • Center for Cancer and Blood Disorders, Bethesda, MD.

ORCID-Profile: Jonathan W Friedberg, Christopher A Yasenchak

Zitieren

APA

Friedberg, J. W., Bordoni, R., Patel-Donnelly, D., Larson, T., Goldschmidt, J., Boccia, R., Cline, V. J. M., Mamidipalli, A., Liu, J., Akyol, A., & Yasenchak, C. A. (2024). Brentuximab vedotin with dacarbazine or nivolumab as frontline cHL therapy for older patients ineligible for chemotherapy. Blood. https://doi.org/10.1182/blood.2022019536

Vancouver

Friedberg JW, Bordoni R, Patel-Donnelly D, Larson T, Goldschmidt J, Boccia R, et al. Brentuximab vedotin with dacarbazine or nivolumab as frontline cHL therapy for older patients ineligible for chemotherapy. Blood. 2024. doi:10.1182/blood.2022019536

BibTeX
@article{Friedberg2024,
  author = {Friedberg, Jonathan W and Bordoni, Rodolfo and Patel-Donnelly, Dipti and Larson, Timothy and Goldschmidt, Jerome and Boccia, Ralph and Cline, Vivian J M and Mamidipalli, Adrija and Liu, Jingmin and Akyol, Alev and Yasenchak, Christopher A},
  title = {Brentuximab vedotin with dacarbazine or nivolumab as frontline cHL therapy for older patients ineligible for chemotherapy},
  journal = {Blood},
  year = {2024},
  doi = {10.1182/blood.2022019536}
}
Kostenlos starten →